BioNote, Inc. (KRX: 377740)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,770.00
-5.00 (-0.10%)
Dec 20, 2024, 9:00 AM KST

BioNote Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Operating Revenue
99,80690,081479,657622,355631,50540,047
Other Revenue
00-0-0--
Revenue
99,80690,081479,657622,355631,50540,047
Revenue Growth (YoY)
9.55%-81.22%-22.93%-1.45%1476.89%-
Cost of Revenue
51,441101,739139,186110,35251,95021,345
Gross Profit
48,365-11,659340,471512,003579,55418,703
Selling, General & Admin
22,09522,78731,51924,34013,1025,051
Research & Development
13,14913,40516,13811,3007,6123,628
Other Operating Expenses
248.83168.12176.92345.2945.4630.88
Operating Expenses
36,82935,51045,06243,25521,5238,775
Operating Income
11,536-47,168295,410468,748558,0319,928
Interest Expense
-253.58-602.82-84.44-44.25-172.63-468.26
Interest & Investment Income
20,02424,6309,715873.6337.5643.83
Earnings From Equity Investments
---147,264---
Currency Exchange Gain (Loss)
-6,13610,16424,51224,159-5,726272.84
Other Non Operating Income (Expenses)
1,454420.84-296.63-123.11-75.83-2.81
EBT Excluding Unusual Items
26,624-12,556181,992493,612552,0949,774
Gain (Loss) on Sale of Investments
-55,300-88,791219,374376,239143,115-826.93
Gain (Loss) on Sale of Assets
-181.22265.213,41233.39-11.4516,271
Asset Writedown
--8,409----
Pretax Income
-28,857-109,491414,778869,885695,19825,218
Income Tax Expense
-69,212-88,994106,980193,284166,9694,605
Net Income
40,355-20,497307,798676,601528,22920,613
Net Income to Common
40,355-20,497307,798676,601528,22920,613
Net Income Growth
---54.51%28.09%2462.62%-
Shares Outstanding (Basic)
10210294949484
Shares Outstanding (Diluted)
10210294949484
Shares Change (YoY)
1.91%8.29%0.64%0.14%11.08%-
EPS (Basic)
395.59-200.993277.217232.045646.12244.74
EPS (Diluted)
394.18-201.003264.007222.005646.00244.74
EPS Growth
---54.80%27.91%2206.94%-
Free Cash Flow
32,480-8,156206,834485,966213,2288,333
Free Cash Flow Per Share
318.02-79.882193.655186.942279.1598.94
Dividend Per Share
200.000200.000----
Gross Margin
48.46%-12.94%70.98%82.27%91.77%46.70%
Operating Margin
11.56%-52.36%61.59%75.32%88.37%24.79%
Profit Margin
40.43%-22.75%64.17%108.72%83.65%51.47%
Free Cash Flow Margin
32.54%-9.05%43.12%78.09%33.77%20.81%
EBITDA
19,718-38,962301,861472,854559,91811,338
EBITDA Margin
19.76%-43.25%62.93%75.98%88.66%28.31%
D&A For EBITDA
8,1828,2066,4514,1061,8871,410
EBIT
11,536-47,168295,410468,748558,0319,928
EBIT Margin
11.56%-52.36%61.59%75.32%88.37%24.79%
Effective Tax Rate
--25.79%22.22%24.02%18.26%
Advertising Expenses
-2,4142,3321,063540.13354.15
Source: S&P Capital IQ. Standard template. Financial Sources.